ClinicalTrials.gg
CompletedNCT05372991Updated Jan 27, 2023

Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop

A Phase 1/2 interventional study of CBT-009 and Vehicle in Myopia, Progressive, sponsored by Cloudbreak Therapeutics, LLC. Completed at 1 site in Australia. Open to participants aged 18 Years to 36 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-27.

Sponsored by Cloudbreak Therapeutics, LLC · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 36 Years
Sex
All
01

Study summary

This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

CBT-009 has the active ingredient of atropine, which at low doses, has shown to be effective in slowing down myopic deterioration. Current atropine products are prone to degradation once the container is open to the air. ADS Pharmaceutical has developed a novel atropine formulation.

Read the detailed description

Type of Study:

Stage 1: Single center, open-labeled, vehicle-controlled, single ascending dose.

Stage 2: Parallel, double-masked, randomized, vehicle-controlled with dosing once-daily in one eye.

Study Population:

Male or female healthy volunteers aged 18-36 years.

Number of Subjects and Sites:

Stage 1: Enrollment is planned for approximately 32 healthy volunteers with 8 subjects per cohort for a total of 4 cohorts.

Stage 2: Enrollment is planned for approximately 50 healthy volunteers with 25 subjects per cohort for a total of 2 cohorts.

Duration of Study Participation:

Stage 1: One day. Stage 2: 28 days of treatment with no follow-up observations.

02

Conditions studied

  • Myopia, Progressive

Browse trials for

03

In context

Myopia, Degenerative

71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.

This study's enrollment of 84 is below the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.

Browse Myopia, Degenerative studies →

Lead sponsor

Cloudbreak Therapeutics, LLC is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 36 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy volunteer without any active ocular diseases

  • 18-36 years of age
  • Able to provide written and comply with study assessments for the full duration of the study

Exclusion criteria

Exclusion Criteria:

Uncontrolled systemic disease

  • Active ocular disease
  • Any ocular surgical procedure within the last 3 months
  • Current enrollment in an drug or device study or participation in such as study within 30 days prior to entry into this study
  • Any condition or situation which, in the investigator's opinion, may put the volunteer at significant risk, may confound the study results, or may interfere significantly with the volunteer's participation in the study. Allergic or sensitive to Atropine study medication or formulation
  • Smoking during the study
  • Female patients who are pregnant, nursing, or planning a pregnancy during the study
  • Current or anticipated use of topical ophthalmic medications are prohibited during the study. Volunteers must have discontinued use of ophthalmic medications for at least 2 weeks prior to Day 1 visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Active comparator
    0.025% atropine sulphate

    The comparator formulation of 0.025% atropine sulfate monohydrate in normal saline will be prepared by diluting commercial 1% atropine sulphate solution with physiologic saline.

    Drug: Atropine Sulfate

  • Placebo comparator
    vehicle

    CBT-009 vehicle formulation is a proprietary sterile ophthalmic solution that does not contain CBT-009 drug substance.

    Drug: Vehicle

  • Experimental
    CBT-009, Low Dose

    CBT-009 low dose formulation is a proprietary sterile ophthalmic solution that contain low dose of CBT-009 drug substance.

    Drug: CBT-009

  • Experimental
    CBT-009, Mid Dose

    CBT-009 mid dose formulation is a proprietary sterile ophthalmic solution that contain mid dose of CBT-009 drug substance.

    Drug: CBT-009

  • Experimental
    CBT-009, High Dose

    CBT-009 high dose formulation is a proprietary sterile ophthalmic solution that contain high dose of CBT-009 drug substance.

    Drug: CBT-009

Interventions

  • This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

    Also known as: Atropine

  • DrugVehicle

    This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

    Also known as: Without Atropine

  • This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

    Also known as: 0.025% eyedrop aqueous solution

06

What researchers measure

Primary outcomes

  1. Safety on near visual acuity

    Near visual acuity will be assessed using best-corrected distance spectacle correction with a reduced logMAR reading chart placed at 40 cm under well-lit conditions at Day 28.

    Time frame: 28 days

  2. Safety on accommodation

    The accommodation will be measured using a near point rule with best-corrected distance spectacle correction at Day 28.

    Time frame: 28 days

  3. Safety on mesopic and photopic pupil

    Mesopic pupil size and photopic pupil size will be measured with a pupillometer at Day 28.

    Time frame: 28 days

07

Study locations

1 site
  • USC
    Brisbane, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Jan 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2021
First posted
May 13, 2022
StartActual
Jul 20, 2022
Primary completionActual
Jan 18, 2023
CompletionActual
Jan 20, 2023
Last update
Jan 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05372991
Lead sponsor
Cloudbreak Therapeutics, LLC
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
May 13, 2022
Start date
Jul 20, 2022
Primary completion
Jan 18, 2023
Completion
Jan 20, 2023
Last update
Jan 27, 2023

Study contacts

Tanya Revell, MD
principal investigator · University of Sunshine Coast,Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion